- $4.05bn
- $3.45bn
- $1.11bn
Brief: Alkermes PLC Reports Financial Results For The Fourth Quarter And Year Ended Dec. 31, 2022 And Provides Financial Expectations For 2023
Alkermes Plc expected to post earnings of 5cents a share - Earnings Preview
Alkermes up as skin cancer drug gets 'Innovation Passport' tag from UK regulator
Brief: Alkermes Awarded Innovation Passport Designation By UK For Treatment Of Mucosal Melanoma
Brief: Alkermes Receives Interim Award In Arbitration Proceedings With Janssen Pharmaceutica
Biotech enters new year with worst days behind - Mizuho
U.S. STOCKS ON THE MOVE-Trip.com, Verizon Communications, Netflix
U.S. STOCKS ON THE MOVE-Reviva, AbCellera, Verizon
Biotech enters new year with worst days behind - Mizuho
U.S. STOCKS ON THE MOVE-UniQure, Select Energy Services, Service Corporation International
U.S. STOCKS ON THE MOVE-Chegg, Yum Brands, Humana
Corrected: BUZZ-Alkermes rises on oncology business spinoff plans
Alkermes Plc reports results for the quarter ended in September - Earnings Summary
Brief: Alkermes PLC Announces Intent To Separate Oncology Business
Brief: Alkermes PLC Reports Third Quarter 2022 Financial Results
Alkermes Plc expected to post earnings of 3cents a share - Earnings Preview
Acorda gains as arbitration panel awards $16.5 million from Alkermes
Europe Research Roundup: Aramis Group Sas, Elis SA, Reckitt
Alkermes Plc reports results for the quarter ended in June - Earnings Summary